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Background. Next-generation sequencing of cancers has identified important therapeutic targets and biomarkers. The goal of this
pilot study was to compare the genetic changes in a human papillomavirus- (HPV-)positive and an HPV-negative head and neck
tumor. Methods. DNA was extracted from the blood and primary tumor of a patient with an HPV-positive tonsillar cancer and
those of a patient with an HPV-negative oral tongue tumor. Exome enrichment was performed using the Agilent SureSelect All
Exon Kit, followed by sequencing on the ABI SOLiD platform. Results. Exome sequencing revealed slightly more mutations in
the HPV-negative tumor (73) in contrast to the HPV-positive tumor (58). Multiple mutations were noted in zinc finger genes
(ZNF3, 10, 229, 470, 543, 616, 664, 638, 716, and 799) and mucin genes (MUC4, 6, 12, and 16). Mutations were noted in MUC12
in both tumors. Conclusions. HPV-positive HNSCC is distinct from HPV-negative disease in terms of evidence of viral infection,
p16 status, and frequency of mutations. Next-generation sequencing has the potential to identify novel therapeutic targets and
biomarkers in HNSCC.
1. Introduction
Tobacco use has steadily declined over the last four decades
[1]. In parallel, there has been a decline in cancers of most
sites in the upper aerodigestive tract [2]. The exception to this
trend is cancers of the oropharynx, particularly those of the
palatine and lingual tonsils, which are caused by oncogenic
subtypes of the human papillomavirus (HPV) [3]. The rise
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in incidence of HPV-positive head and neck squamous cell
carcinoma (HNSCC) has been dramatic, causing the rates of
tonsillar cancer to increase by as much as threefold in some
countries [3, 4]. HPV-positive patients experience markedly
better survival, and their tumors are molecularly distinct
from traditional head and neck cancers [5]. Overexpression
of p16 and proteolysis of p53 are nearly universal in HPV-
positive tumors, in contrast to frequent loss of p16 and
point mutations in p53 that are found in HPV-negative
cancers [5]. However, the specific mechanisms responsible
for improved survival in HPV-positive patients have not been
fully elucidated.
Next-generation sequencing has yielded important
insights into the pathogenesis of other cancers by identi-
fying biomarkers and therapeutic targets. High-throughput
sequencing of HNSCC tumors has recently been reported,
and NOTCH inactivation was the most significant finding
[6, 7]. This pilot study aims to contrast the mutations seen
in an HPV-positive and an HPV-negative tumor using whole
exome sequencing and further our understanding about the
mutations that define HNSCC.
2. Methods
2.1. Patient Selection and Tumor and Blood Sample Collection.
Ethics approval was obtained from Western University Hea-
lth Sciences Research Ethics Board. Informed consent was
obtained from patients undergoing ablative surgery for head
and neck cancer to have a portion of their tumor stored,
a 10mL blood sample taken, and their clinical parameters
prospectively collected. Two patients were identified for this
pilot study: a 49-year-old nonsmoking male with a T2N0
tonsillar cancer treated with transoral robotic surgery and
neck dissection and an 81-year-old female with a history
of heavy smoking with a T2N0 oral tongue cancer treated
with partial glossectomy, neck dissection, and free flap
reconstruction. Primary site tumor specimens were taken
from the center of the resection specimen. Ten mL of
venous blood were drawn intraoperatively into heparinized
collection tubes.
2.2. p16 Immunohistochemistry. For each patient, a portion
of the primary tumor was fixed in formalin and embedded
in paraffin. The blocks were then sectioned (5 µm thick).
p16 immunohistochemistry was performed as previously
described using a mouse monoclonal antibody against
p16 (MTM Laboratories, Heidelberg, Germany) at 1 : 500
dilution [8]. Immunohistochemistry scoring was conducted
by two study pathologists (BW and KK) blinded to HPV
status and patient information. Scoring was as described by
Begum et al. with strong and diffuse staining (>80 percent
of tumor cells) regarded as a positive result, and negative if
absent or focal [9].
2.3. DNA Extraction from Blood and Tumor Tissue. DNA
was extracted from 10mL of whole blood using the QIAmp
Blood Maxi kit following instructions provided by the man-
ufacturer (Qiagen, Valencia, CA, USA). DNA was extracted
Table 1: Primers for HPV testing.
Name Sequence 5′ to 3′
GAPDH F GCTCATTTGCAGGGGGGAGCC
GAPDH R CTGATGATCTTGAGGCTGTTG
HPV 16 F TTGCAGATCATCAAGAACACGTAGA
HPV 16 R GTAGAGATCAGTTGTCTCTGGTTGC
HPV 18 F CAACCGAGCACGACAGGAACG
HPV 18 R TAGAAGGTCAACCGGAATTTTCAT
F: forward, R: reverse.
from approximately 25mg of primary tumor using the
AllPrep DNA/RNA/Protein kit (Qiagen).
2.4. In Situ Hybridization for Human Papillomavirus Testing.
Slides were deparaffinized by immersion in xylene, rehy-
drated in alcohol, and rinsed in water. Slides were then
treated with 20 µg/mL proteinase K (Sigma, St. Louis, MO)
for 30 minutes, followed by immersion in 0.3% H2O2 in
methanol at room temperature for 20 minutes. Slides were
then treated for 10 minutes with avidin solution followed by
biotin solution. The DakoGenpoint (Dako, Carpinteria, CA,
USA) biotinylated probe that identifies high-risk subtypes
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 was added
to the slides. The slides were then covered and heated to 92◦C
for 5minutes and then incubated at 37◦C for 18 hours. DNA-
DNA hybrids were detected by successive incubation with
1 : 100 diluted primary horseradish peroxidase-conjugated
streptavidin (streptavidin-HRP) for 15min, with biotinyl-
tyramide for 15min, and with secondary streptavidin-HRP
for 15min. A cervical cancer was used as a positive control,
and a tonsil specimen from a healthy child undergoing
tonsillectomy for sleep apnea was used as a negative control.
Punctuate hybridization signals localized to the tumor
cell nuclei defined an HPV-positive tumor. Scoring was
conducted by the two study pathologists (BW and KK).
2.5. PCR Confirmation of Patient HPV Status. Patient DNA
was extracted from thin section tissue slices. Briefly, a single
pathology slide from each patient was deparaffinized, and
then the tumor tissue was scraped into a 1.5mL eppendorf
tube containing 50 µL of Arcturus PicoPure extraction buffer,
containing proteinase K (Applied Biosystems). The sample
was digested at 65◦C for 16 hours. The proteinase K was inac-
tivated at 95◦C for 10 minutes, and DNA was used directly
in PCR. Primers were designed against unique regions of
the E6-E7 loci of HPV type 16 and type 18 and synthesized
by Sigma Genosys (Oakville, Canada, Table 1). Primers were
also synthesized against GAPDH, a cellular gene used as
a positive control for the PCR reactions. 0.2 µL of DNA
extracted from the tumor tissue was added to the appropriate
reaction tubes. PCR products were amplified with DNA
Phusion polymerase (Thermo Scientific, Nepean, Canada) in
20 µL reactions following the manufacturer’s instructions.
2.6. Exome Sequencing. Exome libraries were created at The
Centre for Advanced Genomics (Toronto, Canada) according
to the manufacturer’s standard protocol for SOLiD library
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preparation (Applied Biosystems, Carlsbad, CA, USA). Three
µg of genomic DNA extracted from matched patient blood
and tumor samples was sheared via sonication using the
Covaris (S-Series) instrument. The ends of fragmented DNA
were repaired and ligated to SOLiD P1 and A1 adapters
provided in the Agilent Human All Exon 50Mb Kit following
the manufacturers protocol (Agilent, Santa Clara, CA, USA).
The exomes were then captured using the Agilent Human All
Exon 50Mb kit, and the amplified library was purified with
AMPure XP beads (Beckman Coulter Genomics, Danvers,
MA). Sequencing was performed with the SOLiDToP Paired
End Sequencing Kit (Applied Biosystems). The image data
collected was analyzed using the ABI corona pipeline to
generate DNA reads that were mapped to the reference
human genome (UCSC’s hg19) using BFAST [10].
2.7. Bioinformatics. Samples were processed as matched
sets through the Genome Analysis ToolKit (GATK) v1.3-
16 pipeline [11]. Samples were initially locally realigned
using the IndelRealigner walker from the GATK package
with known insertions and deletions found in dbSNP 135.
This was followed by base quality recalibration from GATK.
Default parameters were used for both steps except for
SOLiD specific parameters in the recalibration step. Reads
without any color space calls were marked as failing vendor
quality and thus were removed from further downstream
analysis. In addition, reads that had a reference base inserted
into the reads due to inconsistent color space calls had those
bases set to Ns with base qualities of zero. Finally variants
were called and filtered using the GATK UnifiedGenotyper
and VariantFiltration walkers again with default settings.
To be considered for further downstream analysis, a
tumor variant had to have at least 8x coverage within the
target regions 37,038,261 sites (71.86%) for the HPV-positive
tumor and 39,150,091 sites (75.96%) for the HPV-negative
tumor that met this criterion. In addition to coverage,
the following requirements had to be identified by the
VariantFiltration walker:
(i) variant quality equal to or greater than 30,
(ii) variant confidence/quality by depth (QD) equal to or
greater than 2.0,
(iii) MQ0 < 4 and MQ0/(1.0 ∗ DP)) < 0.1, where MQ0
is the total mapping quality zero reads and DP is the
unfiltered read depth.
A reference variant required a minimum read depth
of 8x within the target region for further consideration
(38,673,520 sites (75.03%) and 38,058,450 sites (73.84%) for
HPV-positive and HPV-negative tumors, resp.). This presen-
ted 36,020,799 and 37,049,778 comparable sites in the HPV-
positive and HPV-negative tumors. Using in-house custom
Perl code, somatic variants within the targeted regions were
identified. To be classified as a somatic variant the following
conditions had to be met: (1) a tumor variant was identified
by GATK that met the above filtration requirements and
(2) the corresponding position in the normal sample
had 8x coverage and did not have a GATK variant call.
Table 2: Patient demographics.
Patient 1 Patient 2
HPV positive HPV negative
Age 49 81
Gender Male Female
Primary site Tonsil Oral tongue
Stage T2N0 T2N0
Smoking Nonsmoker 50 pack years
Alcohol Nondrinker Rare
Differentiation Moderate Moderate to poorly
Adverse features Perineural invasion Perineural invasion
p16 Positive Negative
HPV Positive Negative
Treatment TORS + ND
Transoral resection,
ND, RFFF
HPV: human papillomavirus, TORS: transoral robotic surgery, ND: neck
dissection, and RFFF: radial forearm free flap.
Somatic variants were annotated with refGene annotations
(http://varianttools.sourceforge.net/Annotation/RefGene),
and consequences were identified using ANNOVAR v2012-
03-08 [12].
3. Results
3.1. p16 Immunohistochemistry and HPV Testing. Genomic
DNAwas extracted frommatching tumor and blood samples
from two head and neck cancer patients: patient 1 was a
49-year-old nonsmoking and nondrinking male, and patient
2 was an 81-year-old female smoker. Patient demograph-
ics, treatment details, and histopathologic parameters are
outlined in Table 2. Tumor sections from each patient were
stained with hematoxylin and eosin (Figures 1(a) and 1(b)).
Patient 1 stained diffusely positive for p16 (Figure 1(c)),
while the tumor tissue from patient 2 was negative for p16
(Figure 1(d)). In situ hybridization testing with the broad-
spectrumHPV probe demonstrated strong punctate staining
within nuclei of the tumor of patient 1, consistent with high-
risk HPV infection (Figure 1(e)). HPV-specific, punctate
nuclear staining was absent in the tumor of patient 2
(Figure 1(f)).
We employed primers designed specifically against
unique portions of the E6-E7 region of HPV type 16 and type
18 to confirm the HPV status of the patients in this study.
The GAPDH control was amplified from both patients; as
expected, only patient 1 was HPV type 16 positive (Figure 2).
Patient 2 was negative for HPV type 16, and both patients
were HPV type 18 negative (data not shown).
3.2. Exome Capture and Raw Sequencing Results. The exomes
from tumor tissue and matched blood samples from each
patient were sequenced. For each tumor or blood sample,
approximately 1.2 billion bases were sequenced, 86% of
which were specific for exome sequences. The mean coverage
of the exome targets was 28.1-fold, with 91.6% of the targets
being sequenced at least once and 67.4% sequenced at
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Figure 1: Tumors from two patients were sectioned. Slices were stained with ((a) and (b)) H&E, ((c) and (d)) p16, or ((e) and (f)) HPV in
situ hybridization. Panels represent magnified images of the complete section (inset).
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Figure 2: PCR confirmation of the presence of HPV type 16 DNA
in patient 1 and the absence of HPV type 16 sequences in patient 2.
least ten times. The exome capture and sequencing results
were within the normal range of performance specified
by the manufacturer and are comparable with published
results [13].
3.3. Bioinformatic Interpretation of Sequencing Results. We
compared the sequencing results of each patient’s tumor
to their matched blood samples in order to eliminate
background germline variations and to focus on somatic
alterations unique to the tumor genome. Although the
exome capture is designed to target coding regions, some
intergenic and intron regions adjacent exons are cap-
tured in the process. A complete listing of the identified
variants in coding and noncoding regions for the HPV-
positive and HPV-negative tumors is reported in Tables S1
and S2, respectively (see Supplementary Material available
online at doi: 10.5402/2012/809370). Only the variants that
occurred within exons are listed in Tables 3 and 4. Fifty-
eight somatic mutations were noted in the HPV-positive
tumor, 32 of which were nonsynonymous mutations within
exons. Seventy-three mutations were observed in the HPV-
negative tumor, including 36 coding mutations. Forty-nine
of the mutated genes identified in this study were also
ISRN Oncology 5
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Figure 3: Detection of HPV 16 sequences with the exome captures of the four patient samples. Short read sequences generated from the
exome sequencing data denoted by the small bars were found exclusively in the DNA from the HPV-positive tumor but not in the matched
blood from the same patient or the HPV-negative patient’s tumor or blood with the exception of the nonspecific poly-A signal.
shown to harbor mutations in large-scale sequencing studies
(Tables S1 and S2) [6, 7].
No mutations were noted in TP53, CDKN2A (p16), or
the NOTCH receptors in either tumor. However, multiple
mutations were noted in zinc finger genes (ZNF3, 10, 229,
470, 543, 616, 664, 638, 716, and 799) and mucin genes
(MUC4, 6, 12, and 16). Mutations were noted in MUC12 in
both tumors.
Patient characteristics, PCR analysis, in situ hybridization
testing, and immunohistochemistry all indicated that patient
1 was HPV type 16 positive (HPV type 18 negative by
PCR) and that patient 2 was HPV negative (both type 16
and type 18 negative). When we used our four compiled
exome sequences (blood and tumor from both patients)
as queries against the HPV type 16 genomic sequence
(RefSeq NC 001526.2), the tumor sequence from patient 1
matched numerous regions (39 hits) of the HPV 16 genome
(Figure 3). Matches were identified to all the HPV type 16
genes (except E4) suggesting that the HPV type 16 genome
had integrated into the tumor genome of patient 1. The
tumor sample from patient 2 and the blood samples from
both patients did not align to any specific HPV sequences.
4. Discussion
HPV-positive head and neck squamous cell carcinoma
(HNSCC) has been described as molecularly distinct from
traditional head and neck cancer [5]. The human papil-
lomavirus (HPV) oncoproteins E6 and E7 promote car-
cinogenesis by degrading the tumor suppressors p53 and
retinoblastoma protein (Rb), respectively. In contrast, p53
is not degraded in HPV-negative HNSCC but is frequently
mutated, and p16 is often lost through homozygous deletion,
methylation, or, less frequently, point mutation [5, 14]. This
might lead one to believe that carcinogens like tobacco
and alcohol would promote HNSCC comprised of a large
number of mutations inmany different pathways. In contrast
HPV-positive cancers, modulated by the activities of viral
oncoproteins, might not accumulate a large number of
cellular mutations. In our study, we provided quadruple
confirmation of tumor HPV status with p16 immuno-
histochemistry, HPV in situ hybridization, HPV detection
by PCR, and detection of the HPV 16 genome sequences
within patient 1’s sequenced exome. We observed more
mutations in the HPV-negative tumor when compared to
the HPV-positive tumor, although the absolute difference
was not dramatic (73 versus 58, resp.). Two large-scale
exome sequencing efforts characterizing HNSCC have been
reported recently [6, 7]. The study led by Stransky et al.
reported twice as many mutations in the HPV-negative sam-
ples (4.83mutations/Mb versus 2.28mutations/Mb) [7]. The
second group examined a set of 32 patients, four of which
were HPV positive and reported on a subset of mutations
that were identified by exome sequencing and confirmed
by PCR. In this subset of genes, there were four times as
many mutations in the HPV-negative tumors (20.6 ± 16.7
versus 4.8 ± 3 mutations in the HPV-positive tumors) [6].
Given the broad range of mutations seen in the HPV-
negative cancers, our finding of slightly more mutations in
the HPV-negative tumor is consistent with their results. As
expected we did not identify TP53 or p16 mutations in the
HPV-positive tumor; however these two genes appeared as
wild type in the HPV-negative tumor as well. The lack of
a p16 mutation in the setting of low expression levels as
evidenced by immunohistochemistry may reflect that it has
been inactivated by promoter methylation, the second most
common cause of p16 loss [14].
Only a single genetic mutation (Muc12) was shared by
both HPV-positive and HPV-negative tumor samples. The
cell surface associated Muc12 was the only mucin identified
in the HPV-negative tumor. In contrast, the HPV-positive
tumor had five mutations in four different mucin genes,
including the secreted Muc6, and the transmembrane bound
Muc4, Muc12 and Muc16. Stransky et al. reported mutations
in all the above mucins except for Muc12 [7]. Mucins
are known to be involved in the development of epithelial
cancer where they are often overexpressed, disrupting the
epithelial cell polarity and promoting the epithelial to
mesenchymal transition (EMT) phenotype [15]. Multiple
damaging mutations within the mucins of HPV-positive
tumor may suggest another cellular difference between these
two distinct tumor types.
We also found multiple mutations in the zinc finger
(ZNF) family genes in both tumor types. The ZNF family
represents a large group of molecules which are involved
in various aspects of transcriptional regulation [16]. There
were almost twice as many ZNF mutated genes in the HPV-
positive sample. Although there were a total of 11 ZNF
mutations between the two tumor types, there were no
shared ZNFmembersmutated in both cancers. Stransky et al.
6 ISRN Oncology
T
a
bl
e
3:
C
od
in
g
m
u
ta
ti
on
s
in
th
e
H
P
V
-p
os
it
iv
e
tu
m
or
.
C
h
r
Po
si
ti
on
R
ef
er
en
ce
al
le
le
Tu
m
or
al
le
le
Z
yg
os
it
y
db
SN
P
ID
R
eg
io
n
Ty
pe
G
en
e
Tr
an
sc
ri
pt
n
am
e
E
xo
n
C
D
S
p
os
it
io
n
P
ro
te
in
ch
an
ge
St
an
sk
y∗
A
gr
aw
al
∗∗
19
15
78
91
40
A
G
H
om
o
rs
60
92
90
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
C
Y
P
4F
12
N
M
02
39
44
3
c.
A
26
8G
p.
I9
0V
Ye
s
10
88
94
68
76
G
A
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
FA
M
35
A
N
M
01
90
54
8
c.
G
22
27
A
p.
D
74
3N
3
51
93
08
50
T
C
H
om
o
rs
57
85
96
38
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
IQ
C
F1
N
M
15
23
97
3
c.
A
16
9G
p.
K
57
E
7
20
18
07
17
C
G
H
om
o
rs
37
35
61
5
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
A
C
C
1
N
M
18
27
62
7
c.
G
24
11
C
p.
R
80
4T
Ye
s
14
64
88
23
80
A
G
H
et
er
o
rs
19
50
90
2
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
T
H
FD
1
N
M
00
59
56
6
c.
A
40
1G
p.
K
13
4R
7
10
06
34
19
4
C
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
12
N
M
00
11
64
46
2
2
c.
C
35
0G
p.
A
11
7G
19
90
06
66
7
A
G
H
om
o
rs
75
10
19
43
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
16
N
M
02
46
90
44
c.
T
39
58
1C
p.
I1
31
94
T
Ye
s
19
90
74
12
2
T
G
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
16
N
M
02
46
90
3
c.
A
13
32
4C
p.
T
44
42
P
Ye
s
3
19
55
17
75
3
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
4
N
M
01
84
06
2
c.
G
69
8A
p.
G
23
3E
Ye
s
11
10
17
38
1
G
C
H
et
er
o
rs
34
91
28
94
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
6
N
M
00
59
61
61
c.
C
54
20
G
p.
T
18
07
S
Ye
s
19
50
86
55
35
A
G
H
om
o
rs
67
63
14
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
N
A
P
SA
N
M
00
48
51
2
c.
T
11
9C
p.
I4
0T
4
17
03
45
83
5
G
C
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
N
E
K
1
N
M
00
11
99
39
7
31
c.
C
30
91
G
p.
Q
10
31
E
17
31
95
48
5
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
3A
1
N
M
00
25
50
1
c.
G
39
2A
p.
R
13
1Q
3
98
07
30
75
A
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
5K
4
N
M
00
10
05
51
7
1
c.
A
37
8G
p.
I1
26
M
Ye
s
5
14
05
90
76
6
A
G
H
om
o
rs
29
10
00
6
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
C
D
H
B
12
N
M
01
89
32
1
c.
A
22
87
G
p.
K
76
3E
12
27
78
78
78
G
A
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
P
FI
B
P
1
N
M
00
11
98
91
6
4
c.
G
10
0A
p.
D
34
N
15
43
82
72
61
G
C
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
P
IP
5K
1
N
M
00
11
90
21
4
30
c.
C
38
32
G
p.
H
12
78
D
1
12
85
33
78
T
G
H
et
er
o
rs
11
23
30
88
6
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
R
A
M
E
F1
N
M
02
30
13
2
c.
T
2G
p.
M
1R
Ye
s
X
13
59
56
57
5
G
A
H
et
er
o
rs
78
64
67
93
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
R
B
M
X
N
M
00
21
39
9
c.
C
90
2T
p.
P
30
1L
6
33
27
28
55
G
C
H
om
o
rs
20
71
88
8
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
TA
P
B
P
N
M
17
22
08
4
c.
C
77
9G
p.
T
26
0R
12
11
18
30
46
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
TA
S2
R
31
N
M
17
68
85
1
c.
G
88
9A
p.
V
29
7M
12
11
21
39
69
A
G
H
et
er
o
rs
25
99
40
2
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
TA
S2
R
46
N
M
17
68
87
1
c.
T
92
5C
p.
S3
09
P
Ye
s
3
10
00
84
42
5
T
G
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
T
O
M
M
70
A
N
M
01
48
20
12
c.
A
18
10
C
p.
K
60
4Q
Ye
s
9
13
52
77
00
7
C
T
H
om
o
rs
37
39
91
6
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
T
T
F1
N
M
00
73
44
2
c.
G
12
02
A
p.
R
40
1Q
Ye
s
19
38
37
86
59
A
T
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
W
D
R
87
N
M
03
19
51
6
c.
T
55
35
A
p.
N
18
45
K
9
74
97
56
45
C
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
FA
N
D
5
N
M
00
11
02
42
1
2
c.
G
50
C
p.
G
17
A
12
13
37
32
81
8
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F1
0
N
M
01
53
94
5
c.
C
98
6T
p.
S3
29
F
19
44
93
37
06
C
T
H
et
er
o
rs
57
01
46
90
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F2
29
N
M
01
45
18
6
c.
G
12
50
A
p.
S4
17
N
Ye
s
19
57
08
90
50
C
T
H
et
er
o
rs
48
01
17
7
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F4
70
N
M
00
10
01
66
8
6
c.
C
12
53
T
p.
T
41
8I
Ye
s
19
52
61
84
97
A
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F6
16
N
M
17
85
23
4
c.
T
19
20
A
p.
N
64
0K
Ye
s
2
71
65
41
75
G
A
H
om
o
rs
18
04
02
0
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F6
38
N
M
00
12
52
61
2
24
c.
G
51
76
A
p.
V
17
26
M
7
57
52
89
23
G
C
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F7
16
N
M
00
11
59
27
9
4
c.
G
75
6C
p.
W
25
2C
C
h
r:
ch
ro
m
os
om
e,
∗ m
u
ta
ti
on
s
pr
es
en
t
in
St
ra
n
sk
y
et
al
.,
Sc
ie
n
ce
20
11
[7
],
∗∗
m
u
ta
ti
on
s
pr
es
en
t
in
A
gr
aw
al
et
al
.,
Sc
ie
n
ce
20
11
[6
],
H
om
o:
h
om
oz
yg
ou
s,
H
et
er
o:
h
et
er
oz
yg
ou
s.
ISRN Oncology 7
T
a
bl
e
4:
C
od
in
g
m
u
ta
ti
on
s
in
th
e
H
P
V
-n
eg
at
iv
e
tu
m
or
.
C
h
r
Po
si
ti
on
R
ef
er
en
ce
al
le
le
Tu
m
or
al
le
le
Z
yg
os
it
y
db
SN
P
ID
R
eg
io
n
Ty
pe
G
en
e
Tr
an
sc
ri
pt
n
am
e
E
xo
n
C
D
S
p
os
it
io
n
P
ro
te
in
ch
an
ge
St
an
sk
y∗
A
gr
aw
al
∗∗
2
73
67
92
56
C
G
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
A
LM
S1
N
M
01
51
20
8
c.
C
55
99
G
p.
L1
86
7V
Ye
s
10
37
45
15
86
G
A
H
et
er
o
rs
12
76
68
84
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
A
N
K
R
D
30
A
N
M
05
29
97
16
c.
G
17
42
A
p.
G
58
1E
Ye
s
9
33
38
57
33
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
A
Q
P
7
N
M
00
11
70
7
c.
G
65
7A
p.
M
21
9I
17
42
27
16
63
G
C
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
A
T
X
N
7L
3
N
M
00
10
98
83
3
12
c.
C
10
12
G
p.
P
33
8A
6
13
65
99
91
3
A
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
B
C
LA
F1
N
M
00
10
77
44
1
4
c.
T
10
6A
p.
S3
6T
1
26
64
67
26
A
G
H
et
er
o
rs
10
71
84
9
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
C
D
52
N
M
00
18
03
2
c.
A
11
9G
p.
N
40
S
1
26
64
67
30
A
G
H
om
o
rs
17
64
5
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
C
D
52
N
M
00
18
03
2
c.
A
12
3G
p.
I4
1M
19
42
21
39
48
C
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
C
E
A
C
A
M
5
N
M
00
43
63
2
c.
C
41
4G
p.
F1
38
L
12
31
24
23
62
A
G
H
et
er
o
rs
39
50
58
8
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
D
D
X
11
N
M
03
06
53
8
c.
A
81
8G
p.
K
27
3R
Ye
s
15
83
65
78
20
G
C
H
et
er
o
E
xo
n
ic
St
op
lo
ss
FA
M
10
3A
1
N
M
03
14
52
3
c.
G
50
C
p.
X
17
S
6
76
02
31
30
T
G
H
om
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
FI
LI
P
1
N
M
01
56
87
5
c.
A
24
18
C
p.
Q
80
6H
,
Ye
s
1
15
21
91
70
9
C
G
H
et
er
o
rs
66
62
45
0
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
H
R
N
R
N
M
00
10
09
93
1
3
c.
G
23
96
C
p.
S7
99
T
Ye
s
9
21
20
21
36
A
G
H
et
er
o
rs
14
57
94
21
5
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
IF
N
A
7
N
M
02
10
57
1
c.
T
29
C
p.
V
10
A
7
10
06
35
10
3
A
C
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
U
C
12
N
M
00
11
64
46
2
2
c.
A
12
59
C
p.
E
42
0A
17
10
40
44
35
T
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
Y
H
1
N
M
00
59
63
27
c.
A
37
30
C
p.
K
12
44
Q
Ye
s
Ye
s
18
47
36
40
86
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
M
Y
O
5B
N
M
00
10
80
46
7
37
c.
G
49
39
A
p.
D
16
47
N
Ye
s
12
57
10
66
59
C
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
N
A
C
A
N
M
00
11
13
20
3
10
c.
G
26
74
C
p.
E
89
2Q
Ye
s
1
21
79
53
33
C
G
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
N
B
P
F3
N
M
03
22
64
3
c.
C
28
6G
p.
Q
96
E
Ye
s
Ye
s
10
11
53
70
27
4
T
C
H
om
o
rs
10
74
91
38
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
N
R
A
P
N
M
00
61
75
30
c.
A
34
42
G
p.
I1
14
8V
Ye
s
Ye
s
11
48
34
69
16
G
C
H
om
o
rs
77
06
92
83
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
4C
3
N
M
00
10
04
70
2
1
c.
G
42
4C
p.
V
14
2L
Ye
s
11
46
08
04
6
T
A
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
52
I2
N
M
00
10
05
17
0
1
c.
T
4A
p.
C
2S
11
56
12
80
81
A
G
H
et
er
o
rs
10
89
62
90
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
8J
1
N
M
00
10
05
20
5
1
c.
A
35
9G
p.
Y
12
0C
Ye
s
11
56
14
38
23
G
A
H
om
o
rs
77
61
49
49
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
O
R
8U
1,
O
R
8U
8
N
M
00
10
05
20
4
1
c.
G
72
4A
p.
G
24
2S
X
82
76
40
42
G
C
H
et
er
o
rs
59
21
97
9
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
O
U
3F
4
N
M
00
03
07
1
c.
G
71
0C
p.
G
23
7A
Ye
s
19
43
70
96
56
C
G
H
om
o
rs
11
88
32
78
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
P
SG
4
N
M
21
36
33
1
c.
G
33
C
p.
Q
11
H
Ye
s
14
21
51
14
97
C
T
H
om
o
rs
12
43
46
9
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
R
N
A
SE
7
N
M
03
25
72
2
c.
C
34
6T
p.
H
11
6Y
1
15
30
04
85
3
C
T
H
om
o
rs
37
95
38
2
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
SP
R
R
1B
N
M
00
31
25
2
c.
C
32
T
p.
T
11
I
6
33
41
02
73
T
A
H
om
o
Sp
lic
in
g
N
A
SY
N
G
A
P
1
N
M
00
67
72
14
c.
23
36
+
2T
>
A
12
11
17
43
27
C
T
H
et
er
o
rs
72
47
54
81
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
TA
S2
R
19
N
M
17
68
88
1
c.
G
84
4A
p.
G
28
2R
12
11
18
36
76
C
T
H
et
er
o
rs
73
04
90
72
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
TA
S2
R
31
N
M
17
68
85
1
c.
G
25
9A
p.
V
87
I
7
35
24
40
86
A
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
T
B
X
20
N
M
00
10
77
65
3
7
c.
T
99
9A
p.
N
33
3K
21
10
91
03
47
A
G
H
et
er
o
rs
15
04
82
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
T
P
T
E
N
M
19
92
61
22
c.
T
14
09
C
p.
L4
70
P
7
99
66
91
49
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F3
N
M
03
29
24
6
c.
G
95
8A
p.
A
32
0T
19
57
83
91
50
A
G
H
om
o
rs
81
00
49
1
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F5
43
N
M
21
35
98
4
c.
A
32
0G
p.
Q
10
7R
Ye
s
12
12
44
97
11
9
T
A
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F6
64
N
M
00
12
04
29
8
5
c.
T
42
8A
p.
F1
43
Y
19
12
50
18
52
C
T
H
et
er
o
E
xo
n
ic
N
on
sy
n
on
ym
ou
s
Z
N
F7
99
N
M
00
10
80
82
1
4
c.
G
13
60
A
p.
G
45
4R
Ye
s
C
h
r:
ch
ro
m
os
om
e,
∗ m
u
ta
ti
on
s
pr
es
en
t
in
St
ra
n
sk
y
et
al
.,
Sc
ie
n
ce
20
11
[7
],
∗∗
m
u
ta
ti
on
s
pr
es
en
t
in
A
gr
aw
al
et
al
.,
Sc
ie
n
ce
20
11
[6
],
H
om
o:
h
om
oz
yg
ou
s,
H
et
er
o:
h
et
er
oz
yg
ou
s.
8 ISRN Oncology
reported 50% of the same ZNF mutations that we found in
both tumor samples suggesting that genetic changes to this
family of transcription regulators may be important in the
development of HNSCC [7]. Not enough is known about
the role of mucins and ZNF proteins in HNSCC. These
molecules may warrant further study.
We confirmed that the sequence from the human patho-
gen HPV type 16 was identified within exome sequence of
a HNSCC tumor. In order for HPV to be oncogenic, the
viral E2 protein, which represses the expression of E6 and
E7, must be lost [17]. This only occurs during integration
when the episomal HPV DNA breaks within the E2 gene.
PCR detection of E6 and E7 can detect both episomal and
integrated forms and thus cannot distinguish between a
superficial HPV infection and integrated viral DNA causing
the cancer [17]. An additional benefit of whole exome
sequencing is the detection of integrated HPV DNA. In
Stransky’s study, exome sequencing appeared even more
sensitive than PCR for detection of HPV, as it identified the
presence of HPV 16 in 14 of 73 cases versus 11 for PCR [7].
Perhaps more interesting is the concept of screening human
disease genomes against pathogen datasets. In fact, it was
this exact strategy that led to the discovery of Merkel cell
polyomavirus in 2008 [18]. It may be that a subset of other
cancers have a yet undiscovered viral etiology.
This study represents a pilot effort to gain experience
with this exciting new technology, which was instructive as
our group moves forward with large-scale projects. In addi-
tion to the small sample size, the quality of data generated
limited by the ABI SOLiD platform with an average 30-fold
coverage with 50 base pair paired-end reads yielded only 10-
fold coverage over approximately two-thirds of the coding
sequence. Thus, approximately a third of the exome was
not adequately evaluated and important mutations could
have beenmissed.We have recently completed characterizing
a panel of head and neck cancer cell lines with 100-fold
coverage with 100 base pair paired-end reads, and the results
were vastly superior [19]. An average of 99% of the targeted
exome had at least 10 reads and 90% had fiftyfold coverage.
Perhaps more importantly, an expert bioinformatics team
is critical to properly analyze the data. Although there are
standard steps involved with aligning the sequencing data
to the reference genome, false positive results can be freq-
uent without adequate quality control measures. A carefully
validated pipeline is necessary to filter spurious results in
order to generate valid data.
It should be noted that tremendous insights can be gai-
ned by exome sequencing; however, whole genome sequenc-
ing offers the advantage to identify other genetic changes that
can lead to tumorigenesis including copy number variation
and translocations, in addition to point mutations, inser-
tions, and deletions. Alterations in noncoding regions that
may be important, such as promoters and miRNAs, would
also be identified. The study by Stransky et al. reported whole
genome sequencing in two patients and revealed markedly
more translocations in the HPV-negative versus the HPV-
positive tumors [7]. Ideally, future large-scale initiatives will
be carried out using this more extensive but also more
expensive technique to identify additional important genetic
changes underlying HNSCC.
5. Conclusions
Whole exome sequencing of head and neck cancers can
provide important insights into the molecular biology of the
disease. HPV-positive and negative head and neck cancers
are molecularly distinct, and HPV-negative cancers tend
to harbor more mutations. Multiple, integrated HPV 16
sequences were identified in the exome targets from the
HPV positive patient. These matches were restricted to the
HPV-positive patient’s tumor profile providing evidence of
the utility of screening exome sequences against pathogen
databases.
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